Phys · pharmacological
Opioid, Benzodiazepine and Alcohol Withdrawal
Also known as Opioid, Benzodiazepine and Alcohol Withdrawal · opioid benzodiazepine and alcohol withdrawal · alcohol withdrawal syndrome · delirium tremens · AWS · CIWA-Ar · COWS · opioid use disorder · benzodiazepine withdrawal
Consultant-physician guide to alcohol, benzodiazepine and opioid withdrawal for FRACP DWE and DCE preparation: NICE alcohol withdrawal and Wernicke recommendations, benzodiazepine tapering, opioid detoxification and maintenance, naloxone reversal and relapse-prevention pharmacotherapy.
Checked against its sources on 23 Oct 2026
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Acute alcohol withdrawal with, or at high risk of, withdrawal seizures or delirium tremens — NICE advises admission for medically assisted withdrawal
- Suspected Wernicke's encephalopathy — NICE advises parenteral thiamine for a minimum of 5 days unless Wernicke's is excluded
- Abrupt discontinuation of benzodiazepines in a physically dependent patient can cause serious and potentially life-threatening withdrawal
- Loss of opioid tolerance after detoxification raises the risk of overdose and death, which alcohol or benzodiazepines may potentiate
Opioid, Benzodiazepine and Alcohol Withdrawal
The answer first
Three syndromes, three different rule-sets. In alcohol withdrawal, decide who needs admission, give thiamine to those at risk of Wernicke's encephalopathy, and consider a benzodiazepine (or carbamazepine) on a symptom-triggered regimen in hospital. In benzodiazepine dependence, never stop abruptly; taper slowly. In opioid dependence, NICE advises methadone or buprenorphine first-line for detoxification and recommends both as options for maintenance; naloxone reverses overdose. [1] [3] [4] [5]
References19ShowHide
- [1]National Institute for Health and Care Excellence Alcohol-use disorders: diagnosis and management of physical complications (CG100) — Recommendations NICE, 2017.Source
- [2]National Institute for Health and Care Excellence Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115) — Recommendations NICE, 2014.Source
- [3]National Institute for Health and Care Excellence Drug misuse in over 16s: opioid detoxification (CG52) — Recommendations NICE, 2007.Source
- [4]National Institute for Health and Care Excellence Methadone and buprenorphine for the management of opioid dependence (TA114) NICE, 2007.Source
- [5]Brunner E, Chen CA, Klein T, et al. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. Journal of general internal medicine, 2025.PMID 40526204
- [6]Holleck JL, Merchant N, Gunderson CG Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of general internal medicine, 2019.PMID 30937668
- [7]Dixit D, Endicott J, Burry L, et al. Management of Acute Alcohol Withdrawal Syndrome in Critically Ill Patients. Pharmacotherapy, 2016.PMID 27196747
- [8]Tidwell WP, Thomas TL, Pouliot JD, et al. Treatment of Alcohol Withdrawal Syndrome: Phenobarbital vs CIWA-Ar Protocol. American journal of critical care : an official publication, American Association of Critical-Care Nurses, 2018.PMID 30385536
- [9]Kessel KM, Olson LM, Kruse DA, et al. Phenobarbital Versus Benzodiazepines for the Treatment of Severe Alcohol Withdrawal. The Annals of pharmacotherapy, 2024.PMID 38247044
- [10]Shah P, Stegner-Smith KL, Rachid M, et al. Front-Loaded Versus Low-Intermittent Phenobarbital Dosing for Benzodiazepine-Resistant Severe Alcohol Withdrawal Syndrome. Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2022.PMID 35668289
- [11]McPheeters M, O'Connor EA, Riley S, et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA, 2023.PMID 37934220
- [12]Kranzler HR, Soyka M Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. JAMA, 2018.PMID 30167705
- [13]Shulman M, Wai JM, Nunes EV Buprenorphine Treatment for Opioid Use Disorder: An Overview. CNS drugs, 2019.PMID 31062259
- [14]Britch SC, Walsh SL Treatment of opioid overdose: current approaches and recent advances. Psychopharmacology, 2022.PMID 35385972
- [15]Baandrup L, Ebdrup BH, Rasmussen JØ, et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. The Cochrane database of systematic reviews, 2018.PMID 29543325
- [16]US National Library of Medicine DailyMed Naloxone hydrochloride injection — prescribing information DailyMed, 2026.Source
- [17]US National Library of Medicine DailyMed SUBOXONE (buprenorphine and naloxone) sublingual film — prescribing information DailyMed, 2025.Source
- [18]US National Library of Medicine DailyMed Acamprosate calcium delayed-release tablets — prescribing information DailyMed, 2026.Source
- [19]US National Library of Medicine DailyMed Thiamine hydrochloride injection — prescribing information DailyMed, 2026.Source